長效型持續釋放藥物之注射式凝膠組成物及其製備方法LONG-ACTING, SUSTAINED DRUG DELIVERY, INJECTABLE GEL COMPOSITION AND FABRICATING METHOD THEREOF

專利類型

發明

專利國別 (專利申請國家)

中華民國

專利申請案號

103135071

專利證號

I 569809

專利獲證名稱

長效型持續釋放藥物之注射式凝膠組成物及其製備方法LONG-ACTING, SUSTAINED DRUG DELIVERY, INJECTABLE GEL COMPOSITION AND FABRICATING METHOD THEREOF

專利所屬機關 (申請機關)

國立交通大學

獲證日期

2017/02/11

技術說明

此可注射式胰島素幾丁聚醣凝膠利用酵素進行凝膠奈米結構降解來控制胰島素之釋放，通過調控幾丁聚醣凝膠濃度以及酵素濃度等參數，可以使膠體降解時間從幾週至幾個月。而經由凝膠的降解，胰島素釋放速度將正比於凝膠降解的速度並且無蛋白質變性的跡象。本發明也成功的在動物實驗中得到證實，只需要注射一次200微升小劑量的幾丁聚醣凝膠，即可成功的控制血糖至少10天。免疫學分析也證實了在凝膠降解的過程中，此胰島素凝膠具有高度生物降解性、生物相容性並且不會引起免疫反應。本發明具有良好的臨床發展潛力可以利用可預測的胰島素釋放凝膠來提供糖尿病病患一種無心身負擔的臨床治療方案，從而大大提高患者的生活品質。 This injectable insulin-carrying colloidal chitosan-based hydrogel where the insulin was released via an enzymatically-induced nanostructure degradation of the colloidal gel. With the control of synthetic parameters included solid content of the colloidal chitosan and enzyme concentration, the colloidal gel can be degraded over a time period ranging from weeks to months. Upon gel degradation, the insulin can then be correspondingly released in a proportion rate related to gel degradation without any sign of protein denaturation. This concept was successfully proved in an animal model where at least 10 days of glucose-reduction efficacy was detected upon a single subcutaneous injection of a small amount the insulin-carrying hydrogel, for instance, 200 uL. Following a subsequent complete gel degradation afterward, together with immunological analysis confirmed this insulin-carrying colloidal hydrogel is highly biodegradable, biocompatible and immunologically-free to the host.

備註

連絡單位 (專責單位/部門名稱)

智慧財產權中心

連絡電話

03-5738251

網址